The World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG) have recommended for approval R21/Matrix-M malaria vaccine.
This has been developed by the University of Oxford and the Serum Institute of India, and leverages Novavax’ (Nasdaq: NVAX) adjuvant technology, R21/Matrix-M malaria vaccine.
Of note, the vaccine demonstrates high efficacy with a reassuring safety profile, with 75% effectiveness over 12 months in Burkina Faso, Kenya, Mali and Tanzania. Moreover, it can be easily deployed and manufactured at mass scale and modest cost - addressing a significant gap in vaccine supply.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze